CFLAR and prostate carcinoma: It was reported that MG132 sensitizes tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant prostate cancer cells by activating the AP-1 signaling pathway, repressing the anti-apoptotic molecule c-FLIP(L) [17].